Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Source: Eur Respir J 2002; 19: 865-871 Year: 2002
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD Source: Eur Respir J 2009; 33: 778-784 Year: 2009
Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Formoterol or tiotropium bromide do not influence isolated nocturnal hypoxemia in stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Effect of budesonide/formoterol, budesonide and terbutaline on exercise-induced bronchoconstriction in mild intermittent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Source: Eur Respir J 2011; 37: 273 Year: 2011
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Source: Eur Respir J 2011; 38: 797-803 Year: 2011